Sutro Biopharma, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen Ahmad from Bank of America Securities reiterated a Sell rating on the stock and has a $0.80 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tazeen Ahmad has given his Sell rating due to a combination of factors related to Sutro Biopharma’s current position and future prospects. The company recently held an R&D Day where they discussed their pipeline, particularly focusing on their proprietary ADC manufacturing platform. While the approach to optimize ADC components for better clinical profiles is promising, all supporting data remains preclinical, necessitating substantial clinical validation to confirm competitive differentiation.
Additionally, Sutro Biopharma is in the early stages of clinical trials for their products, with initial data for STRO-004 expected by mid-2026 and an IND filing for STRO-006 anticipated in mid-2026. The company also introduced STRO-227, their first dual-payload ADC, with an IND filing expected in late 2026 or early 2027. Despite these developments, the current stock price is slightly above the price objective, and the company has yet to demonstrate significant clinical success, leading to the reiteration of an Underperform rating with a price objective of $0.80.
Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of STRO in relation to earlier this year.